Acute porphyria polyneuropathy and positive treatment effect glucose
https://doi.org/10.1234/XXXX-XXXX-2016-7-36-40
Abstract
The athors described the case of acute porphyria polyneuropathy with an effective treatment for glucose. The disease is manifest at the age of 36 years with abdominal pain, bowel clinical paresis. After 3 weeks from the onset of the disease originated tetraparesis due to peripheral nerve lesions with a primary lesion of the proximal extremities. There was a dark urine. There was a tachycardia with a heart rate of 125 1 per minute. The qualitative urine test for porphyria with Ehrlich’s reagent, which was positive. By quantifying total urinary porphyrins porphyrins were increased more than 10 times, porphobilinogen was increased more than 100 times, delta-aminolevulinic acid was increased almost 15-fold. The diagnose was acute porphyria, severe course, sensory-motor polyneuropathy, severe peripheral tetraparesis. The treatment was: glucose given treatment dosage of 100 g, then 250 g of dry matter during the day. Also appointed B vitamins (B1, B6, B12), alpha-lipoic acid 600 mg orally. The was a positive effect of the treatment. The muscle strength triceps muscle and the iliopsoas muscle became 5 points, the strength of the deltoid muscle increased significantly. The strength of the flexors of fingers also increased slightly. Consequently, for treatment of acute porphyria glucose effectively. Glucosa - inhibitor of synthetase enzyme i aminolevulinic acid. Glucose acts weaker arginate gem. Therefore, in the next stage of its inefficiency porphyria treatment prescribed heme arginate. In this case, glucose was effective. Appointment of haem arginate is not needed.
About the Authors
S. V. Kotov
Moscow Regional Research and Clinical Institute
Russian Federation
O. P. Sidorov
Moscow Regional Research and Clinical Institute
Russian Federation
References
1. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010 Mar 13;375(9718):924-37. doi: 10.1016/S0140-6736(09)61925-5.
2. Kauppinen R, von und zu Fraunberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem. 2002 Nov;48(11):1891-900. doi: 10.1373/clinchem.2011.162388.
3. Nordmann Y, Puy H, Da Silva V, Simonin S, Robreau AM, Bonaiti C, Phung LN, Deybach JC. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J Intern Med. 1997 Sep;242(3):213-7. doi: 10.1111/imj.13127.
4. Simon NG, Herkes GK. The neurologic manifestations of the acute porphyrias. J Clin Neurosci. 2011 Sep;18(9):1147-53. doi: 10.1016/j.jocn.2011.01.003.
5. Straume Z, Skuja V, Proskurina A, Malina J, Hasnere S, Krupnova I, Lejnieks A, Derovs A. Think porphyria: case report and review of literature. Eksp Klin Gastroenterol. 2015;(7):69-77.
Views:
913